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esponsibility of Xi’Abstract A dissolution test for fesoterodine low dose extended-release tablets using liquid chromato-
graphic (LC) method equipped with a C18 monolithic column was developed and validated. LC system
was operated isocratically at controlled temperature (40 1C) using a mobile phase of acetonitrile:
methanol:0.03 M ammonium acetate (pH 3.8) (30:15:55, v/v/v), run at a ﬂow rate of 1.5 mL/min and
detected at 208 nm. The best dissolution conditions for this formulation were achieved using a USP
apparatus 2 (paddle) at 100 rpm and 900 mL of phosphate buffer at pH 6.8 as the dissolution medium.
Validation parameters such as the speciﬁcity, linearity, accuracy, precision, and robustness were evaluated
according to international guidelines, giving results within the acceptable range. The kinetic parameters of
drug release were also investigated using model-dependent methods and the dissolution proﬁles were best
described by the Higuchi model. The validated dissolution test can be applied for quality control of this
formulation.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The drug release kinetics follows a well deﬁned behavior in order
to supply the maintenance dose enabling the attainment of the
desired drug concentration. Thus, the use of mathematical model-
ing turns out to be very useful for the prediction of release kinetics.
There are a number of kinetic models, which describe the overall1
ity. Production and hosting by Elsevie
rg/licenses/by-nc-nd/4.0/).
2 27962541.
o.com.br (M.S. Sangoi).
an Jiaotong University.release of drug from the dosage forms. Therefore, developing tools
that facilitate product development by reducing the necessity of
bio-studies are always desirable [1–3].
Antimuscarinic medications are the ﬁrst-line pharmacotherapy
for overactive bladder (OAB). Fesoterodine (FESO; Fig. 1) is an
effective and well-tolerated antimuscarinic agent, in an extended-
release preparation in 4 mg and 8 mg once-daily doses, licensed
for the treatment of symptoms that may occur in patients with
OAB [4]. OAB disorder is a collection of symptoms, in
particular, urinary urgency with or without urgency urinary
incontinence, usually accompanied by increased micturition
frequency and nocturia [5].r B.V. All rights reserved. This is an open access article under the CC BY-
Fig. 1 Chemical structure of fesoterodine fumarate.
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hydrolyzed by nonspeciﬁc esterases to its primary active metabo-
lite 5-hydroxymethyl tolterodine (5-HMT), such that it is unde-
tectable in blood after oral administration [4], and presented in
bioequivalence study of FESO [6]. Then, the antimuscarinic
activity of FESO is solely due to 5-HMT. Besides, there is a
further hepatic metabolism of 5-HMT, forming three inactive
metabolites [7], and ﬂip-ﬂop pharmacokinetic in that the terminal
half-life of 5-HMT is observed due to the extended-release rate
from the formulation [4]. Thus, to compare responses of 5-HMT in
bioassays and parent drug in physicochemical test is complex and
more studies are required to establish an in vitro–in vivo correla-
tion [8–10].
Some analytical methods were developed and validated for
FESO determination in pharmaceutical formulation [11–14].
Therefore, the aim of the present study was to develop and
validate a dissolution test for FESO tablets using monolithic liquid
chromatography (LC) method. The monolithic columns represent
an approach that provides high rates of mass transfer at lower
pressure drops as well as high efﬁciencies even at elevated ﬂow
rates [11]. Moreover, the release kinetics was determined using
model-dependent approaches.2. Experimental
2.1. Chemicals
FESO fumarate reference substance was purchased from Toronto
Research Chemicals Inc. (Toronto, ON, Canada). Toviazs (Pﬁzer
Inc., Zwickau, Germany) extended-release tablets, containing 8 mg
of FESO fumarate (6.2 mg of FESO base), were obtained from
commercial sources. All chemicals used were of pharmaceutical or
special analytical grade. Ultrapure water (Milli Q Gradient System,
Millipore Corp., Bedford, MA, USA) was used for all the
analyses.
2.2. Instrumentation
A Vankels VK 7010 (Vankel Technology Group, Cary, USA)
dissolution station multi-bath (n¼8) with a VK 8000 dissolu-
tion auto-sampling station, VK type bidirectional peristaltic
pump and VK 750D digitally controlled heater/circulator
was used.
A Shimadzu LC system (Shimadzu Corp, Kyoto, Japan)
equipped with an SCL-10AVP system controller, an LC-
10ADVP binary pump, an SIL-10ADVP autosampler, a CTO-
10ACvp column oven, and an SPD-M10AVP photodiode array(PDA) detector was used. The detector was set at 208 nm and
peak areas were integrated automatically by computer using
Class VP software (v 6.12).
2.3. Analytical conditions
A reversed-phase Phenomenex Inc. (Torrance, CA, USA) Onyx
C18 monolithic column (100 mm 4.6 mm i.d.) was used.
A security guard holder was used to protect the analytical column.
The Shimadzu LC system was operated isocratically at controlled
temperature (40 1C) using a mobile phase of acetonitrile:metha-
nol:0.03 M ammonium acetate (pH 3.8) (30:15:55, v/v/v), run at a
ﬂow rate of 1.5 mL/min and detected at 208 nm. The injection
volume was 25 μL. Published LC method was optimized to
improve the sensitivity [12].
2.4. Dissolution test conditions
Dissolution testing was performed in compliance with USP 34
[15] using 900 mL of dissolution medium pre-heated at
3770.5 1C. The effects of rotation speed, ﬁlters and dissolution
medium were evaluated using a paddle (USP apparatus 2).
Automatic sampling was performed using 5 mL aliquots and these
solutions were immediately ﬁltered through 70 μm ﬁlters con-
nected into the equipment. The dissolution samples were analyzed
by the LC method at predetermined time intervals (1, 2, 4, 6, 8 and
12 h). The cumulative percentage of drug release was plotted
against time, in order to obtain the release proﬁle and to calculate
the in vitro dissolution data (n¼6).
2.5. Determination of sink conditions and ﬁlter suitability
FESO sink conditions were determined in water, 0.01 and 0.1 M
HCl, sodium acetate buffer pH 4.5, and phosphate buffer pH 6.8
and pH 7.5, using an equivalent to three times of the dose in the
pharmaceutical formulation. Vessels (n¼3) containing 250 mL of
medium were preheated in a thermostatically controlled water bath
at 3770.5 1C, before adding an excess of FESO. The suspensions
were gently agitated. Aliquots of 5 mL were removed from each
vessel after 16 h and ﬁltered. The ﬁltered samples were directly
analyzed by LC method. The sink conditions were desirable, but
not mandatory.
The ﬁlter evaluation is essential to determine if it can be used in
the dissolution test without adsorption of the drug and if it
removes insoluble excipients that may otherwise cause high
background or turbidity [15]. FESO sample solution was prepared
in dissolution medium proposed with a ﬁnal concentration of
6.89 μg/mL. The solution was transferred to the vessel that was
gently rotated for 16 h at 3770.5 1C. Aliquot of this solution was
withdrawn and ﬁltered using 10 μm and 70 μm porous cannula
ﬁlters manufactured from ultra-high molecular weight polyethy-
lene. The same procedure was performed with another aliquot of
the same solution, but this was centrifuged for 5 min at 3000 rpm
instead of being ﬁltered. The solutions were analyzed by LC
method.
2.6. Dissolution method validation
To demonstrate that the method was adequate for dissolution test
purposes, it was validated by LC through the analyses of stability,
speciﬁcity, linearity, accuracy, precision, robustness and ﬁlter
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[15,16].
2.7. Evaluation of release kinetic
To evaluate FESO release kinetics, ﬁve model-dependent
approaches were applied: zero-order, ﬁrst-order, Higuchi, Hix-
son–Crowell, and Korsmeyer–Peppas, whose equations are shown
in Table 1 [1,2]. The curves were constructed applying the kinetic
models cited, considering the sampling time forZ80% of drug
dissolution (t80%). Frequently, pharmacopeias use this parameter as
an acceptance limit for the dissolution test. The mathematical
model that best expressed the dissolution proﬁle of FESO tablets
was selected based on the coefﬁcient of determination (R2) [1].
The experimental data were plotted and evaluated according to
each model [1,2].3. Results and discussion
3.1. Development of the dissolution test
Dissolution tests were initially performed with each dissolution
medium at the stirring rate of 75 rpm to investigate the drug
release. The evaluation of sink conditions for FESO demonstrated
that the drug is soluble in all dissolution media evaluated due to
high aqueous solubility of the drug.
The evaluation of the 10 and 70 μm ﬁlters does not interfere in
the results of the analysis, giving values within 98–102% for the
ﬁltered samples compared with the centrifuged solutions, as
speciﬁed [17]. The 70 μm ﬁlters were used in all analyses.
The USP apparatus 2 (paddles) was chosen due to its
acceptance as a standard procedure for tablets. Paddles are most
used at 50 or 75 rpm, rates outside 25–150 rpm are usually
inappropriate and 100 rpm may be used, especially for extended-
release products [15]. Experimentally, an agitation speed of
100 rpm showed a more rapid release proﬁle than 50 and
75 rpm, maintaining the suitable sink conditions and maximum
differentiation of drug release. Therefore, t80% was obtained in
12 h, in accordance with extended-release formulations and
suitable for pharmacokinetic studies such as in vitro–in vivoTable 1 Mathematical models used for kinetics of drug
release.
Mathematical models Equations
Zero-order Qt¼Q0þk0t
First-order log Qt¼ log Q0þ(k1t)/2.303
Higuchi ft¼kHt1/2
Hixson–Crowell W0
1/3
–Wt
1/3¼kHCt
Korsmeyer–Peppas Qt/Qα¼kKtn
Qt, amount of drug dissolved in time t; Q0, initial amount of drug in
the solution; k0 and k1, zero order and ﬁrst order release constants,
respectively; ft, amount of drug released in time t by surface unity;
kH, Higuchi dissolution constant; W0, initial amount of drug in the
pharmaceutical dosage form; Wt, remaining amount of drug in the
pharmaceutical dosage form at time t; kHC, a constant incorporating
the surface–volume relation; Qα, amount of drug released at inﬁnite
time t; kK, Korsmeyer–Peppas dissolution constant; n release
exponent (indicative of drug release mechanism).correlation. FDA recently published a dissolution method with
phosphate buffer pH 6.8 at 75 rpm and 20 h test. In our tests, the
same condition was performed showing time-consuming and
principally less differentiation response, which can affect pharma-
cokinetic studies.
The dissolution medium was selected based on a screening
study with paddles, at stirring rate of 100 rpm, with 900 mL of
water, 0.01 and 0.1 M HCl, sodium acetate buffer (pH 4.5),
phosphate buffer pH 6.8 and pH 7.5. The results showed that
phosphate buffer pH 6.8 was the best dissolution medium, since it
provided the highest drug release percentage and ensured sink
conditions. Therefore, the method screening was desired in order
to obtain an adequate differentiation of the drug release, improving
the potential discriminative power of the method.
Based on these results, USP apparatus 2 at stirring rate of
100 rpm was selected as the dissolution apparatus and 900 mL
of phosphate buffer pH 6.8 was chosen as the dissolution
medium.3.2. Validation of the method
The stability test of the reference substance solution and samples
demonstrated that FESO was stable in the test conditions for up to
16 h at temperature of 3770.5 1C and after 24 h at room
temperature (2472 1C), using freshly prepared solutions as
reference. There was no evidence of degradation of FESO under
these conditions. According to the literature [15], the acceptable
range for solution stability was 98–102% of the initial value.
The speciﬁcity of the dissolution test by the LC method
demonstrated no interference of pharmaceutical excipients. No
chromatographic peak from the placebo formulation was observed
with the same retention time of FESO (Fig. 2). According to the
USP 34 and Pharmacopeial Forum [15,16], the lack of chromato-
graphic peaks from the placebo formulation demonstrates the
speciﬁcity of the method.
The three analytical curves constructed for FESO were found to
be linear in the range of 1.0–8.0 mg/mL (1.0, 2.0, 4.0, 6.0 and
8.0 μg/mL). The value of the determination coefﬁcient calculated
(R2¼0.9974, y¼34328xþ6634.8, where x is the concentration
and y is the peak absolute area) indicated the linearity of the
analytical curve for the method.
Moreover, according to Pharmacopeial Forum the linearity
should be evaluated from about 20% of expected concentration
to about 20% above the maximum possible concentration [17].
Commercial tablets containing 6.2 mg FESO base have a release
maximum of the 6.89 mg/mL. As t80% was evaluated, relative to
5.51 mg/mL, 20% and 120% of this are in the range performed.
The accuracy was demonstrated by the recovery of known
amounts of FESO to the dissolution vessels. Concentrations of
1.38, 6.89, and 8.27 μg/mL (corresponding respectively to 20%,
100%, and 120% of the nominal assay concentration) were
evaluated and mean recoveries were 1.35, 7.19 and 8.57 μg/mL,
respectively, corroborating the accuracy of the method. Percentage
recoveries from 95% to 105% were recommended for the accuracy
test [15,16].
Intra-day precision was determined by triplicate injection of
each solution and the intermediate precision was evaluated at three
different concentration levels (1.38, 6.89, and 8.27 μg/mL) in 3
days. The low relative standard deviation (RSD) (r5%) demon-
strated adequate precision of the method. The results of accuracy
and precision are presented in Table 2.
Table 2 Accuracy and precision of the dissolution the method.
Concentration
(μg/mL)
Day Accuracy
(recovery, %)
Precision
(RSD, %)
Intra-
day
Inter-
day
Intra-
day
Inter-
day
1.38 1 97.93 97.98 4.74 3.51
2 97.88 3.02
3 98.14 4.20
6.89 1 104.76 104.42 3.66 2.26
2 103.60 0.96
3 104.91 2.14
8.27 1 102.95 103.74 2.90 1.97
2 103.32 0.70
3 104.96 1.85
RSD¼ relative standard deviation.
Table 3 Drug release of fesoterodine in different pH values
of buffer solution during robustness testing.
Time (h) Drug release (%) Fcalculated
b
pH 6.6 a pH 6.8 a pH 7.0 a
1 16.84 16.81 17.57 2.99
2 26.59 28.34 27.18 3.86
4 43.96 44.62 45.93 2.52
6 56.69 60.35 59.73 4.70
8 66.62 69.05 70.83 4.79
12 79.42 83.17 83.94 4.25
aMean of three tablets.
bFcalculatedoFcritical¼5.14 (P40.05).
Fig. 3 Dissolution proﬁle of fesoterodine low dose extended-release
tablets (n¼6) in phosphate buffer pH 6.8 medium (3770.5 1C) using
apparatus 2 rotating at 100 rpm.
Fig. 2 Chromatograms of fesoterodine reference solution with UV
spectra (A) and placebo sample solution (B) in dissolution medium.
Chromatographic conditions: Phenomenex Onyx C18 monolithic
column (100 mm 4.6 mm i.d.), 40 1C; mobile phase: acetonitrile:
methanol:0.03 M ammonium acetate (pH 3.8) (30:15:55, v/v/v); ﬂow
rate: 1.5 mL/min; detection: 208 nm.
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values of buffer solution (6.6 and 7.0) were analyzed by ANOVA
at each time, showing no signiﬁcative difference among the FESO
released from Toviazs by LC method (FcalculatedoFcritical¼5.14;
P40.05) (Table 3). This data indicated that the proposed method
was robust under the conditions tested.
3.3. Kinetics of drug release
The dissolution proﬁle (Fig. 3) was used to evaluate the kinetics of
drug release. After mathematical modeling of dissolution proﬁledata, graphical plots and the model selection criteria represented
by the determination coefﬁcients and dissolution constants are
presented (Fig. 4). Considering these values, dissolution proﬁles
were better described by the Higuchi model. Higuchi describes
drug release as a diffusion process based in Fick’s law, square root
time dependent. This relationship can be used to describe the drug
dissolution from several types of modiﬁed release pharmaceutical
dosage forms, as in the case of some transdermal systems and
matrix tablets with water soluble drugs, as the Toviazs
[1,2,18,19]. Experimentally, after 16 h of dissolution test, the
matrix physically swelled forming a gel, enabling the drug
dissolution into the matrix and its exit through the outer surface
of gel.4. Conclusions
The dissolution test for FESO tablets was developed and validated
according to the USP 34 and ICH guidelines. In vitro dissolution
proﬁle for FESO was obtained using 900 mL of phosphate buffer
pH 6.8 as dissolution medium, paddle at 100 rpm. The percentage
of drug dissolved was determined by the monolithic-column LC
method and the kinetics of drug release was better described by the
Higuchi model. The proposed method demonstrated to be adequate
for quality control of FESO dosage form, since there is no ofﬁcial
monograph, contributing to assure the therapeutic efﬁcacy of
the drug.
Fig. 4 Graphical plots obtained by ﬁtting experimental release
data of fesoterodine to (A) zero-order, (B) ﬁrst-order, (C) Higuchi,
(D) Hixson–Crowell, and (E) Korsmeyer–Peppas models. R2,
coefﬁcient of determination; k, dissolution constants of respective
mathematical models.
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